comparemela.com

Latest Breaking News On - Pharnext sa stock exchange - Page 1 : comparemela.com

PARIS, France, June 14th, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high. | June 14, 2023

United statesFrance generalFabreguettes leibBella centerEuronext growth stock exchangePeripheral nerve societyPresse financiPharnext sa stock exchangePress releaseIth alpha fr001400gun7

New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on. | May 25, 2023

United statesFrance generalFabreguettes leibShahram attarianUniversity hospital la timoneRare diseases networkNeuromuscular diseases reference centersOpen label phaseOverall neuropathy limitation scaleCharcot marie tooth disease typeOverall neuropathy limitations scaleNeuromuscular diseasesDiseases networkLead investigatorFirst double blind phaseOpen label extension

PARIS, France, May 23th, 2023, 08:30 am CET – Pharnext SCA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high. | May 23, 2023

United statesFrance generalFabreguettes leibEuropean unionUnited statesaEastern europeLatin americaGlobal tech opportunitiesEuronext growthPresse financiPivotal phasePharnext sa stock exchangePress releaseIth alpha fr001400gun7

PARIS, France, May 22th, 2023, 08:30 am CET – Pharnext SCA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high. | May 22, 2023

United statesFrance generalHugo brugiFabreguettes leibEdison groupEdison investment researchJanuary neovacsEuronext growthPresse financiPharnext sa stock exchangePress releaseIth alpha fr001400gun7

PARIS, France, May 12th, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high. | May 12, 2023

United statesFrance generalJavier grandaFabreguettes leibNeurology serviceSpanish society of neurologyNeuromuscular diseases groupEuronext growth stock exchangeSpring meetingNeuromuscular diseases study groupSpanish societyHospital universitario central de asturiasHospital universitario de cabuePresse financiPharnext sa stock exchangePress release

vimarsana © 2020. All Rights Reserved.